Description: ScPharmaceuticals, Inc. is a United States-based biopharmaceutical company. The Company is engaged in developing pharmaceutical products for subcutaneous delivery. The Company offers sc2Wear Infusor, which is a small pump that attaches to the body using a standard medical adhesive. The sc2Wear Infusor injects the drug into the body slowly, similar to an intravenous (IV) drip. The sc2Wear Infusor includes features, such as two-component design, automated safety features and micropiston pump technology. Its pipeline includes product timelines for preclinical, through regulatory approval. Its products will be administered subcutaneously through the sc2Wear Infusor. Its lead products are subcutaneous formulations of furosemide (parenteral diuretic in treating heart failure) and ceftriaxone (parenteral antibiotic outside the hospital setting). Its furosemide formulation has been optimized for use with the sc2Wear Infusor. Its pipeline also includes Ertapenem for subcutaneous delivery.
Home Page: www.scpharmaceuticals.com
SCPH Technical Analysis
2400 District Avenue
Burlington,
MA
01803
United States
Phone:
617 517 0730
Officers
| Name | Title |
|---|---|
| Mr. John H. Tucker | Pres, CEO, Principal Exec. Officer, Principal Financial Officer & Director |
| Ms. Rachael Nokes | Sr. VP of Fin. & Principal Accounting Officer |
| Katherine Taudvin | Director of Corp. Devel. & Investor Relations |
| Dr. John Mohr Pharm.D. | Sr. VP of Clinical Devel. & Medical Affairs |
| Mr. Michael D. Hassman | Sr. VP of Technical Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.4873 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2017-11-17 |
| Fiscal Year End: | December |
| Full Time Employees: | 26 |